APA (7th ed.) Citation

HAN, S., HAN, S., SON, K., & SUNG, Y. (2024). 1859-LB: PG-102, a Novel Bispecific GLP-1R/GLP-2R Fc-Fused Agonist—Data on Safety, Tolerability, and Pharmacokinetics (PK) in Single Ascending Dose Trial in Healthy Subjects and Preliminary Population PK Modeling. Diabetes (New York, N.Y.), 73(Supplement_1), 1. https://doi.org/10.2337/db24-1859-LB

Chicago Style (17th ed.) Citation

HAN, SEUNGHOON, SUNGPIL HAN, KYOUNG-HWA SON, and YOUNGCHUL SUNG. "1859-LB: PG-102, a Novel Bispecific GLP-1R/GLP-2R Fc-Fused Agonist—Data on Safety, Tolerability, and Pharmacokinetics (PK) in Single Ascending Dose Trial in Healthy Subjects and Preliminary Population PK Modeling." Diabetes (New York, N.Y.) 73, no. Supplement_1 (2024): 1. https://doi.org/10.2337/db24-1859-LB.

MLA (9th ed.) Citation

HAN, SEUNGHOON, et al. "1859-LB: PG-102, a Novel Bispecific GLP-1R/GLP-2R Fc-Fused Agonist—Data on Safety, Tolerability, and Pharmacokinetics (PK) in Single Ascending Dose Trial in Healthy Subjects and Preliminary Population PK Modeling." Diabetes (New York, N.Y.), vol. 73, no. Supplement_1, 2024, p. 1, https://doi.org/10.2337/db24-1859-LB.